Commentary|Videos|March 12, 2024
Evolving and Current Standards of Care for HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Advertisement
Advertisement
Trending on OncLive
1
China's NMPA Approves Pirtobrutinib Across CLL
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5